Idera Releases Preclinical Hyperlipidemia Data On TLR Antagonist
Idera’s proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and is said to present a potentially new approach for the treatment of certain autoimmune diseases.
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
The company said that the certification represents a step toward achieving one of the company’s major goals for its labelstock and RFID facilities worldwide: developing Environmental Management Systems
iGCP trials conform to a set of internationally recognised ethical and scientific quality requirements, providing assurance that data is credible and accurate. Ensuring e-Therapeutics’ clinical trials comply with